header logo image


Page 14«..10..13141516..2030..»

Archive for the ‘Genetic Engineering’ Category

Lords seek to allow gene-editing in UK ‘to produce healthy, hardier crops’ – The Guardian

Wednesday, June 17th, 2020

Peers are preparing plans to legalise the gene-editing of crops in England, a move that scientists say would offer the nation a chance to develop and grow hardier, more nutritious varieties. The legislation would also open the door to gene-editing of animals.

The change will be proposed when the current Agriculture Bill reaches its committee stages in the House of Lords next month, and is supported by a wide number of peers who believe such a move is long overdue. At present, the practice is highly restricted by EU regulations.

The plan would involve introducing an amendment to the bill to give the secretary of state for environment, food and rural affairs the power to make changes to the Environmental Protection Act, alterations that would no longer restrict gene-editing in England. The rest of the UK would need separate legislation.

Gene-editing of plants and animals is controlled by the same strict European laws that govern genetically modified (GM) organisms. However, scientists say gene-editing is cheaper, faster, simpler, safer and more precise than GM technology.

As they point out, GM technology involves the transfer of entire genes or groups of genes from one species to another while the more recently developed techniques of gene-editing merely involve making slight changes to existing genes in a plant or animal and are considered to be just as safe as traditional plant breeding techniques.

Early benefits for UK agriculture could include gluten-free wheat, disease-resistant sugar beet and potatoes that are even healthier than those that we have now, said plant scientist Professor David Baulcombe of Cambridge University.

This enthusiasm is also shared by peers who have argued that the wide use of gene editing of crops could give the nation a key advantage in agriculture and in the food industry after Brexit.

Peers have argued gene editing could give the nation a key advantage after Brexit

I would like [to send] a clear message in this bill that we will move forward to allow gene editing in our research programmes, said Lord Cameron during last weeks reading of the bill. This is a way of speeding up the natural methods of farm breeding to ensure that we can improve the environmental and nutritional outcomes of feeding our ever-expanding human population.

And there was clear evidence that the government would also be sympathetic to such a move. On gene editing, the government agrees that the EU approach is unscientific, said Lord Gardiner, who was responding for the government.

By freeing gene-editing from the expensive restrictions imposed by the EU on the growing of GM plants it will also be possible for small and medium-sized enterprises to set up new projects, say supporters.

At present only major corporations can pay the costs of the rigorous trials required when growing GM plants. We are looking for a brighter, greener, more innovative future, and this bill helps farmers produce that, said Conservative peer Lord Dobbs last week.

Read more here:
Lords seek to allow gene-editing in UK 'to produce healthy, hardier crops' - The Guardian

Read More...

2025 Projection: Genetic Engineering Market Strategies and Insight Driven Transformation 2020-2025 – Owned

Wednesday, June 17th, 2020

Research report on global Genetic Engineering market 2020 with industry primary research, secondary research, product research, size, trends and Forecast.

The report presents a highly comprehensive and accurate research study on the globalGenetic Engineering market. It offers PESTLE analysis, qualitative and quantitative analysis, Porters Five Forces analysis, and absolute dollar opportunity analysis to help players improve their business strategies. It also sheds light on critical Genetic Engineering Marketdynamics such as trends and opportunities, drivers, restraints, and challenges to help market participants stay informed and cement a strong position in the industry. With competitive landscape analysis, the authors of the report have made a brilliant attempt to help readers understand important business tactics that leading companies use to maintainGenetic Engineering market sustainability.

Download Premium Sample Copy Of This Report:Download FREE Sample PDF!

Global Genetic Engineering Market to reach USD XX billion by 2025.

Global Genetic Engineering Market valued approximately USD XX billion in 2017 is anticipated to grow with a healthy growth rate of more than XX% over the forecast period 2018-2025. The major driving factor of global Genetic Engineering market are surging utility of technologies such as CRISPR, Talen & ZNF and rising focus on innovation in Gene Therapy in Genetic Engineering. In addition, increasing funding for research and development of medical products is the some other driving factor that drives the market. However, one of the major restraining factors of Genetic Engineering market is high amount of investment. Genetic engineering is also known as genetic modification or genetic manipulation. It is the direct manipulation of an organisms genes using biotechnology. It is a set of technologies used to change the genetic makeup of cells, including the transfer of genes within and across species boundaries to produce improved or novel organisms. Genetic engineering allows of plant or animals to be modified so their maturity can occur at a quicker pace. Genetic modification can also help to create resistance to common forms of forms of organism death. Genetic engineering can also change the traits of plants or animals so that they produce greater yield per plant. Any genetic mutation caused by environmental mutagens may also be corrected through genetic engineering.

The regional analysis of Global Genetic Engineering Market is considered for the key regions such as Asia Pacific, North America, Europe, Latin America and Rest of the World. North America has dominate the market of total generating revenue with 40% across the globe in 2016 due to increasing use of genetic engineering for use of gene therapy, high incidence of cancer and increasing awareness for the use of stem cells. Europe is also contributing second largest major share in the global market of Genetic Engineering. Asia-Pacific region is also anticipated to exhibit higher growth rate / CAGR over the over the coming years due to presence of developing countries, companies grabbing these opportunities and extracting their presence in the region. The Middle East and Africa holds the least share in global genetic engineering market owing to limited availability of medicine facilities.

The major market player included in this report are:

Thermo Fisher Scientific Inc.

Merck KGAA

Horizon Discovery Group Plc

Transposagen Biopharmaceuticals Inc.

New England Biolabs

Genscript Biotech Corporation

Lonza Group Ltd.

Origene Technologies Inc.

Integrated DNA Technologies Inc.

Amgen Inc.

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming eight years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within each of the regions and countries involved in the study. Furthermore, the report also caters the detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, the report shall also incorporate available opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:

By Devices:

oPCR

oGene Gun

oGel Assemblies

oOthers

By Techniques:

oArtificial Selection

oGene Splicing

oCloning

oOthers

By End-User:

oResearch Institutes

oAcademic Institutes

oPharmaceutical Industries

oOthers

By Application:

oAgriculture

oMedical Industry

oForensic Science

oOthers

By Regions:

oNorth America

oU.S.

oCanada

oEurope

oUK

oGermany

oAsia Pacific

oChina

oIndia

oJapan

oLatin America

oBrazil

oMexico

oRest of the World

Furthermore, years considered for the study are as follows:

Historical year 2015, 2016

Base year 2017

Forecast period 2018 to 2025

Target Audience of the Global Genetic Engineering Market in Market Study:

oKey Consulting Companies & Advisors

oLarge, medium-sized, and small enterprises

oVenture capitalists

oValue-Added Resellers (VARs)

oThird-party knowledge providers

oInvestment bankers

oInvestors

Have Any Query Or Specific Requirement?Ask Our Industry Experts!

Table of Contents:

Study Coverage:It includes study objectives, years considered for the research study, growth rate and Genetic Engineering market size of type and application segments, key manufacturers covered, product scope, and highlights of segmental analysis.

Executive Summary:In this section, the report focuses on analysis of macroscopic indicators, market issues, drivers, and trends, competitive landscape, CAGR of the global Genetic Engineering market, and global production. Under the global production chapter, the authors of the report have included market pricing and trends, global capacity, global production, and global revenue forecasts.

Genetic Engineering Market Size by Manufacturer: Here, the report concentrates on revenue and production shares of manufacturers for all the years of the forecast period. It also focuses on price by manufacturer and expansion plans and mergers and acquisitions of companies.

Production by Region:It shows how the revenue and production in the global market are distributed among different regions. Each regional market is extensively studied here on the basis of import and export, key players, revenue, and production.

About Us:

We publish market research reports & business insights produced by highly qualified and experienced industry analysts. Our research reports are available in a wide range of industry verticals including aviation, food & beverage, healthcare, ICT, Construction, Chemicals and lot more. Brand Essence Market Research report will be best fit for senior executives, business development managers, marketing managers, consultants, CEOs, CIOs, COOs, and Directors, governments, agencies, organizations and Ph.D. Students.

Top Trending Reports:

https://brandessenceresearch.com/healthcare/radiotherapy-market-global-size

https://brandessenceresearch.com/technology-and-media/lease-accounting-software-market

Top Trending Reports:

https://www.marketwatch.com/press-release/europe-composite-materials-market-global-industry-analysis-and-opportunity-assessment-2020-2025-2020-06-15?tesla=y

https://www.marketwatch.com/press-release/europe-composite-materials-market-global-industry-analysis-and-opportunity-assessment-2020-2025-2020-06-15?tesla=y

https://www.marketwatch.com/press-release/europe-composite-materials-market-global-industry-analysis-and-opportunity-assessment-2020-2025-2020-06-15?tesla=y

https://www.marketwatch.com/press-release/europe-lipid-nutrition-market-size-growth-opportunity-and-forecast-to-2025-2020-06-09

Continued here:
2025 Projection: Genetic Engineering Market Strategies and Insight Driven Transformation 2020-2025 - Owned

Read More...

Swiss men aspire to live to 108.5 years old – swissinfo.ch

Wednesday, June 17th, 2020

Swiss men have targeted an ideal lifespan of 108.5 years, while women are content with an average of 93.4 years of life. A survey of 2,000 people by the health insurer Sanitas found that many people are making changes to their lifestyle to secure a longer life.

swissinfo.ch/mga

Two thirds of respondents said they are physically active and eat healthy food while more than half refrain from smoking and a fifth abstain from alcohol.

The Health Forecast survey, which aims to come out annually, found that 40% of people currently use an app to monitor their health. More than a quarter of respondents would employ blood and DNA tests to determine optimal nutritional supplements and other tailor-made fitness measures.

Young men, in the 18-29 age range, appear keener than anyone else to actively boost their health and fitness levels. A third of male respondents in this age group (compared to 20% of all ages and genders) would consider biohacking a buzzword that involves enhancing health via diet, exercise, wearables and sometimes implants, such a microchips, or genetic engineering.

Only half as many women in this age group said they would be prepared to go to such lengths.

The survey also reveals more detail on attitudes to genetic science. Some 58% support gene therapy to treat cancer, 54% are in favour of gene diagnostics to diagnose hereditary diseases and 44% welcome prenatal screenings.

But three-quarters of respondents said this science should stop short of active intervention by altering genes or producing clones.

View original post here:
Swiss men aspire to live to 108.5 years old - swissinfo.ch

Read More...

Mosquitoes can be genetically engineered to be resistant to malaria – Massive Science

Wednesday, June 17th, 2020

Our relationship to Neanderthals has been a point of contention for over a century. It all began with an inaccurate reconstruction of the first Neanderthal ever found, which portrayed them as brutish, stooped-over cavemen (turns out, that Neanderthal was an injured old man with arthritis).

But within the last half century, scientists have noticed the many biological and behavioral similarities that show just how close our species are. While these similarities are clear from hard objects like bones and tools, perishable objects, which comprise the majority of material culture items in humans, have been lacking.

Now, scientists have discovered a Neanderthal feat that hammers another nail in the coffin of supposed Neanderthal inferiority. Last month, an international team of researchers found a small section of a twisted cord attached to a stone flake in Neanderthal site in southeastern France, dated to over 40,000 years old. This constitutes the oldest direct evidence of fiber technology ever found.

A stone flake with three distinct twisted fibers preserved (indicated by the box).

M.-H. Moncel

When artifacts are recovered from archaeological sites, they are generally imaged using high powered microscopes to zoom in on tiny marks and details on the stones. Previously, plant fibers had been found on stones at this site, but they were too poorly preserved to be interpreted. When the team examined this particular flake, they were surprised to find three distinct twisted fibers, which were then twisted together in the opposite direction to form a 3-ply cord.

While it may not sound like much, this piece of string hints at something much more significant. For one, extracting and manipulating plant fibers requires working memory, as well as understanding plant seasonality and the concept of numbers. Also, such cords are the building blocks for creating other textiles, such as baskets, fabrics, and nets. Once adopted, these objects would have been indispensable in daily life.

This little piece of string provides unprecedented insight into the lives of our extinct relatives, which, despite an abundance of genetic, archaeological, and skeletal data, have been extremely difficult to interpret. It seems as though we humans arent as unique as we like to think.

Read the rest here:
Mosquitoes can be genetically engineered to be resistant to malaria - Massive Science

Read More...

Podcast: Where did GMOs come from? Former Monsanto scientist Robb Fraley recounts the advent of biotech crops – Genetic Literacy Project

Wednesday, June 17th, 2020

Robb Fraley. Credit: Robert Holly/Big-AgWatch.org

On the five-year anniversary of the Talking Biotech podcast, host and plant geneticist Kevin Folta sits down with former Monsanto chief technology officer Robb Fraley. After growing up on a small farm in Illinois, Fraley earned degrees in microbiology and biotechemistry and played a pivitol role in the development of the first genetically modified crops in the early 1980s.

He recalls the race to transform plants and his work as a leader at Monsanto. While the company did important work to advance crop biotechnology, Fraley says, Monsanto made little effort to explain genetic engineering to food companies, the media and consumers and was thus unprepared for the backlash against GMOs in the 1990s.

It wasnt until many years later that the biotech firm made a concerted effort to join the public discussion about crop biotech. Fraley says this experience transformed his thinking about science communication and his vision for how to talk about the future of food and farming.

Robb Fraley is the former Executive Vice President and Chief Technology Officer at Monsanto Company. He holds a PhD in microbiology and biochemistry from the University of Illinois. Follow him on Twitter @RobbFraley

Kevin M. Folta is a professor in the Horticultural Sciences Department at the University of Florida. Follow Professor Folta on Twitter @kevinfolta

Read more:
Podcast: Where did GMOs come from? Former Monsanto scientist Robb Fraley recounts the advent of biotech crops - Genetic Literacy Project

Read More...

Behind the scenes of exciting biochemical engineering innovation in the US – Study International News

Wednesday, June 17th, 2020

In the School of Chemical, Materials and Biomedical Engineering at the University of Georgia (UGA), biochemical engineering research is driven by innovators in their own right.

Among them is Dr Yajun Yan, a professor who received UGAs 2020 Award for Excellence in Research.

Dr Yan leads research in the microbial production of biofuels and high-value chemicals. In 2018, he was part of the team that developed a new genetic smart circuit to rewire microorganism metabolism, essentially turning them into miniature machines for specific tasks.

Cells are not happy when they are regulated; they will produce only whats necessary for their growth. Our method tells the cell to switch from growth mode to production mode, Dr Yan explained.

Such breakthroughs at UGA consistently lead to the development of new technologies in energy, environment and health. His innovations have received six issued US patents so far.

Thats how Dr Yan came to be named 2018 Academic Entrepreneur of the Year, which recognised his entrepreneurial spirit in advancing scientific impact through start-ups BiotecEra Inc. and HGG Research LLC.

He started BiotecEra Inc. with his colleague Yuheng Lin, to create eco-friendly microbial technologies for pharmaceutical and chemical industries. This includes developing 5-hydroxytryptophan products to address depression, insomnia, and anxiety in humans as well as milk fever in dairy cows.

Source: University of Georgia School of Chemical Materials and Biomedical Engineering

Suffice to say, Dr Yans research and teaching benefit greatly from each other.

My research helps me integrate the emerging concepts and technologies into my teaching materials and inform students of the most recent progress in our field. The interactions with students during my teaching also inspire me to get new ideas and approaches to address many research problems, he shared.

Connecting biochemical engineering niche to network

At its most creative, a scientific mind is a Petri dish for ingenuity. Biochemical engineering students at UGA are aware of their potential to contribute to real-world change, which they go on to cultivate in focused research labs in the School of Chemical, Materials and Biomedical Engineering.

Here, expert faculty members engage PhD and Masters students in research that advances technologies, disciplinary understanding, and the world itself.

This is the importance of leaders like Dr Mark Eiteman from the Comprehensive Molecular Bioengineering Lab. He holds UGAs 2014 Inventors Award, having created several technologies to industrially produce commodity and chemicals using microorganisms.

These include amino acids used in animal feed and nutritional supplements as well as a group of organic acids used in the production of polymers, cosmetics and pharmaceuticals. His inventions have been licensed to four multinational companies, where they are manufactured and distributed for industrial benefit.

On top of that, Dr Eiteman is a named inventor in five US patents and many more abroad.

A firm believer that engineering problems dont have easy answers, Dr Eiteman encourages his students to truly understand the various approaches to solving technical problems.

He believes students bring great diversity to instruction and research. In his words, I have had some students ask me questions or come up with ideas that I never would have thought of, but that often leads to new insights and innovation.

Realise your potential with postgraduate courses

Engineering solutions for the future means optimising renewable sources, and what better energy source to tap into than the sun?

Acknowledging clean energy as the need of the century, Dr Ramaraja Ramasamy, professor and Associate Dean in the UGA College of Engineering, has been working on harvesting electricity directly from plants since 2013.

Source: Shutterstock

For every photon of sunlight a plant captures, it produces an equal number of electrons. This allows them to convert electricity more efficiently than solar panels.

How does this process work?

We have developed a way to interrupt photosynthesis so that we can capture the electrons before the plant uses them to make these sugars, said Dr Ramasamy.

His technology involves separating out thylakoids which capture and store energy from sunlight from plant cells. Then, researchers can manipulate the protein to redirect these electrons through carbon nanotubes.

Dr Ramasamy and his collaborators are working to scale the invention into commercialisation based on this early framework.

In the near term, this technology might best be used for remote sensors or other portable electronic equipment that requires less power to run, he said.

If we are able to leverage technologies like genetic engineering to enhance the stability of the plant photosynthetic machinery, Im hopeful that this technology will be competitive to traditional solar panels in the future.

To join the pursuit for innovation at UGAs School of Chemical, Materials and Biomedical Engineering, take on the MS Biochemical Engineering or PhD in Engineering Biochemical Engineering Emphasis. Students with a background in chemical, environmental, pharmaceutical, biotechnology, biomolecular, or bioprocess engineering are welcome to enrol.

A robust scientific community awaits, ready to tackle persisting challenges with novel solutions and the next big idea could just come from you.

Follow the University of Georgia on Facebook, Twitter, Instagram, YouTube and LinkedIn

Cutting-edge research at the frontier of science and engineering

How biomedical engineering research creates transformative real-world impact

See original here:
Behind the scenes of exciting biochemical engineering innovation in the US - Study International News

Read More...

Genetically Modified Crops Market Earnings Margins, Value Of Production & Consumption Demand Figures 2020-2026 – 3rd Watch News

Wednesday, June 17th, 2020

Genetically Modified Crops Market report provide the COVID19 Outbreak Impact analysis of key factors influencing the growth of the market Size (Production, Value and Consumption). This Genetically Modified Crops industry splits the breakdown (data status 2014-2020 and Six years forecast 2020-2026), by manufacturers, region, type and application. This study also analyses the Genetically Modified Crops market Status, Market Share, Growth Rate, Future Trends, Market Drivers, Opportunities and Challenges, Risks and Entry Barriers, Sales Channels, Distributors and Porters Five Forces Analysis.

Genetically Modified Crops Market competitive landscapes provides details by topmost manufactures like (Monsanto, Dupont Pioneer, Syngenta, Dow, Bayer, Long Ping High-Tech, Shandong Denghai Seeds), including Capacity, Production, Price, Revenue, Cost, Gross, Gross Margin, Growth Rate, Import, Export, Market Share and Technological Developments

Get Free Sample PDF (including COVID19 Impact Analysis, full TOC, Tables and Figures)of Genetically Modified Crops[emailprotected]https://www.researchmoz.us/enquiry.php?type=S&repid=2398459

Genetically Modified Crops Market Competition by Manufacturers (2020 2026): Genetically Modified Crops Market Share of Top 3 and Top 5 Manufacturers, Genetically Modified Crops Market by Capacity, Production and Share by Manufacturers, Revenue and Share by Manufacturers, Average Price by Manufacturers By Market, Manufacturers Manufacturing Base Distribution, Sales Area, Product Type, Market Competitive Situation and Trends, Market Concentration Rate.

Scope of Genetically Modified Crops Market:Genetically modified crops (GM crops or biotech crops) are plants used in agriculture, the DNA of which has been modified using genetic engineering methods. In most cases, the aim is to introduce a new trait to the plant which does not occur naturally in the species. Examples in food crops include resistance to certain pests, diseases, environmental conditions, reduction of spoilage, resistance to chemical treatments (e.g. resistance to a herbicide), or improving the nutrient profile of the crop. Examples in non-food crops include production of pharmaceutical agents, biofuels, and other industrially useful goods, as well as for bioremediation.

Global Genetically Modified Crops market size will increase to xx Million US$ by 2025, from xx Million US$ in 2018, at a CAGR of xx% during the forecast period. In this study, 2018 has been considered as the base year and 2019 to 2025 as the forecast period to estimate the market size for Genetically Modified Crops.

On the basis of product type, this report displays the shipments, revenue (Million USD), price, and market share and growth rate of each type.

Corn Soybean Sorghum Cotton Other

On the basis on the end users/applications,this report focuses on the status and outlook for major applications/end users, shipments, revenue (Million USD), price, and market share and growth rate foreach application.

Scientific Research Agriculture Crops

Do You Have Any Query Or Specific Requirement? Ask to Our Industry[emailprotected]https://www.researchmoz.us/enquiry.php?type=E&repid=2398459

Genetically Modified Crops Market: Regional analysis includes:

The Study Objectives Of This Genetically Modified Crops Market Report Are:

Contact:

ResearchMozMr. Rohit Bhisey,Tel: +1-518-621-2074USA-Canada Toll Free: 866-997-4948Email:[emailprotected]

Browse More Reports Visit @https://www.mytradeinsight.blogspot.com/

Visit link:
Genetically Modified Crops Market Earnings Margins, Value Of Production & Consumption Demand Figures 2020-2026 - 3rd Watch News

Read More...

Know about Impact of Covid-19 on Genome Editing/Genome Engineering Market Influencing Factors by Top Companies like Thermo Fisher Scientific, Merck…

Wednesday, June 17th, 2020

The Genome Editing/Genome Engineering market report focuses on the economic developments and consumer spending trends across different countries for the forecast period 2020 to 2027. The research further reveals which countries and regions will have a better standing in the years to come. Apart from this, the study talks about the growth rate, market share as well as the recent developments in the Genome Editing/Genome Engineering industry worldwide. Besides, the special mention of major market players adds importance to the overall Genome Editing/Genome Engineering market study.

This is the most recent report inclusive of the COVID-19 effects on the functioning of the market. It is well known that some changes, for the worse, were administered by the pandemic on all industries. The current scenario of the business sector and pandemics impact on the past and future of the industry are covered in this report.

The major manufacturers covered in this report:

Thermo Fisher Scientific, Merck KGaA, Horizon Discovery, Genscript USA, Sangamo Biosciences, Integrated DNA Technologies, Origene Technologies, Transposagen Biopharmaceuticals, Lonza Group, New England Biolabs

To Know More about Genome Editing/Genome Engineering Market Get Free Sample Copy of this Report @ https://www.marketographics.com/sample-enquiry-form/4298

Knowing the trends influencing the industry performance

Stakeholders, marketing executives and business owners planning to refer a market research report can use this study to design their offerings and understand how competitors attract their potential customers and manage their supply and distribution channels. When tracking the trends researchers have made a conscious effort to analyze and interpret the consumer behaviour. Besides, the research helps product owners to understand the changes in culture, target market as well as brands so they can draw the attention of the potential customers more effectively.

On the basis of Type Outlook, this report displays the production, revenue, price, market share and growth rate of each type, primarily split into:

CRISPRTALENZFNAntisenseOther Technology

On the basis of Application Outlook, this report displays the production, revenue, price, market share and growth rate of each type, primarily split into:

Cell Line EngineeringAnimal Genetic EngineeringPlant Genetic EngineeringOther

#Genome Editing/Genome Engineering Market Report to grow your business needs and avail !!! Limited Time DISCOUNT Available!!! Get Your Copy at Discounted [emailprotected] https://www.marketographics.com/discount-enquiry-form/4298

Some niche products and services believed to be revenue generators are also included in the report. Apart from this, a wide range of products from various segments and sub-segments expected to present greater opportunities in the Genome Editing/Genome Engineering industry are discussed in the document. Development of new products and substitutes that will completely transform the market dynamics over the forecast period occupies a special section in the report.

Market Segment by Regions, regional analysis covers:

North America (United States, Canada and Mexico)

Europe (Germany, France, UK, Russia and Italy)

Asia-Pacific (China, Japan, Korea, India and Southeast Asia)

South America (Brazil, Argentina, Colombia)

The investigative approach applied for the extensive analysis of the sale, gross margin and profit generated by the industry are presented through resources including tables, charts, and graphic images. Importantly, these resources can be easily integrated or used for preparing business or corporate presentations.

Here are the questions we answer

Browse complete Genome Editing/Genome Engineering report description And Full TOC @ https://www.marketographics.com/industry-reports/genome-editing-genome-engineering-market

To summarize, the global Genome Editing/Genome Engineering market report studies the contemporary market to forecast the growth prospects, challenges, opportunities, risks, threats, and the trends observed in the market that can either propel or curtail the growth rate of the industry. The market factors impacting the global sector also include provincial trade policies, international trade disputes, entry barriers, and other regulatory restrictions.

About Us:With reports from over 500 prominent publishers as well as daily updates on our collection, intended to empower companies and individuals catch-up with vital insights on industries operating across different geographies, along with the trends, share, size and growth rate of market verticals and numerous other services, we have our fingers dipped in just about everything market research-related. Besides meticulously curated research reports, our clients can also access our specialized services without any additional charges to gain vital market insights.

Contact Us:John WatsonHead of Business DevelopmentOffice No, 203 Chandan Nagar,Kharadi Pune, Maharashtra 411014Direct Line:+918484002482Visit our News Site: http://newssucceed.com

Go here to see the original:
Know about Impact of Covid-19 on Genome Editing/Genome Engineering Market Influencing Factors by Top Companies like Thermo Fisher Scientific, Merck...

Read More...

Cut and paste: the true genetic engineering of the coronavirus – Explica

Wednesday, June 17th, 2020

Trees are easier to cut than genes. But with both, in theory, a pandemic can be unleashed. Deforesting and destroying ecosystems We make it easier for animal pathogens to jump on humans. But it is also true that we can know in great detail the source code in which the entrails of new viruses are written. Your genes. And manipulate them.

In Lluis Montolius laboratory, at the CNB-CSIC, they have been tracking the revolutionary CRISPR genetic editing technique for years. A system that allows cut and paste pieces of the genome of a living being with enormous precision, and whose discovery we owe to the Spanish Francis Mojica.

They are now developing this tool to see if it can be useful in destroying the RNA strands of coronaviruses and, therefore, prevent SARS-CoV-2 from replicating in the body. It would be the first time that such a drug is developed. Basically using the smallest scissors in the universe.

Lets start with one of the most common applications of CRISPR: making custom animals and plants. It has been done for about four years relatively regularly in research laboratories.

Mouse | Pests Mice Rats (CC-BY)

Despite the fact that the technique became world famous for the daring of Dr. He Jiankui, in 2018, to manufacture three children edited using this technique something completely illegal CRISPR is useful to make animal models.

The mouse is the classic animal model with which to experiment from antiviral drugs to vaccines. In the case of SARS-CoV-2, Mice are not infectious because they lack the ACE2 receptor that allows the virus to enter cells.

CRISPR is the technique by which, illegally, three Chinese babies were genetically edited to avoid developing AIDS. But it is common in other everyday laboratory uses.

So there are already several laboratories that are developing humanized mice with CRISPR. Human genes or parts thereof are cut and pasted into the genome of a future rodent, almost before it is an embryo.

The mouse that is born will already be able to have those receptors typical of humans (and some other animals) so that, at that level, they look a bit more similar. The next step is to no longer infect the mice. But cure them.

The coronavirus genome is RNA, explains Montoliu. If we have a CAS protein that we can program to cut RNA, why dont we target it to cut the coronavirus genome? And we are directly attacking the heart, the genetic material of that coronavirus, explains the researcher.

The CNB-CSIC researcher Lluis Montoliu | M. Vicious

When he talks about CAS protein, he means those tiny molecular scissors. There are different types. There are real motorized clippers, called CAS9, that can cut the double strand of DNA. So they are as promising as they are disputed: they work on humans.

For an RNA virus (the chain is simple) a manual scissor pruner is enough, to continue with the metaphor. This is where CAS13a or CAS13d enter. They work (thanks to some guides) no matter what strain, variant, or mutant. Interesting, in case the coronavirus begins to change more than it seems, as it happens with the influenza virus.

The small drawback of these scissors (the CAS13a we have hardly known since 2016) is that once they cut the virus, they can be bundled to cut the rest of the cell. When Dr. Feng Zhang (BROAD / MIT), its inventor tested CAS13a for the first time, he saw that it was doing its job well but immediately freaked out and started cutting, unspecifically, the rest of the RNA in that test tube.

Fortunately, the protein has become more sophisticated so that, already with variant 13d, we have a very specific tool, because the cell has its own RNA and we do not have to touch those, they are useful for it to function.

It also wont enter the nucleus of the human cell (DNA) because CAS13d doesnt need it. That would be as risky as driving the chainsaw into the heart of a hedge. There is a risk of cutting it down.

CAS9, used to edit girls from a tomato, is like that chainsaw, hence the delicacy and prematureness of this technique for editing people. The mess of the cellular patchwork that can be mounted is important, until the gluing technique is fine-tuned, although it shows promise. That is, we are controlling the grafting technique, to continue with the garden comparison.

Regarding the coronavirus, this does not mean that we already have a ready-to-use medicine from these CRISPR scissors. First you will have to check if they work In zebrafish embryos, that we will try Seville, where we will deliver together with CAS13 a guide that tells you where you have to cut .

Then it will be tested in laboratory cells infected with other cousin viruses to avoid risks and we will get their cutting patterns. Hence, yes, in the SARS-CoV-2.

Sure we could start doing the experiment on mice, but its very important that lets go step by step Montoliu warns. At least, with the certainty that the method works in cells outside a living being

The project has received 75,000 euros of financing from donations from companies and individuals. When we have verified that it works in cells, we will test it in mice (also edited), after this year. If we see (this year) that we can degrade SARS-CoV-2 in crops it would already be a success.

In April, after theoretical proposals in this regard, researchers from Stanford and Duke universities developed a curative scissors of this type, experimentally viable in human lung cells. They named it PACMAN (Comecocos). Will it work outside the lab loft?

CAS scissors can cut viruses. And if they do, it is because they detect them, so it is possible to use them to do tests, in theory.

Although, to date, the most reliable method to detect the active virus in a person is RT-PCR, exist other genetic screening approaches which have not yet been shown to work, but which are promising. This is the case of this possible pocket PCR, in which Margarita Salas Luis Blancos patent partner works.

The CRISPR genetic cutter can also aid in the detection of coronaviruses. In classic PCR methods and that of Blancos team, the virus is evident because it literally shines in the laboratory. With CRISPR it is possible to shine each cut that scissors, CAS12 in this case, they hit the gene molecule.

There are several methods to experiment with, under the acronyms SHERLOCK and CARMEN. The interesting thing about these technologies is that, combined, they can perform hundreds of tests simultaneously. And not only for detecting SARS-CoV-2, but for 120 different viruses.

CARMEN Test Plate | Michel James, MIT

These are some of the applications of genetic engineering to destroy viruses or to immunize ourselves against them, since there are several biotechnological approaches in the race for the COVID-19 vaccine that involve the manipulation of genes (of the virus, in this case).

Cut. Paste. And create new viruses. Again, and in the sense of some conspiracy theories, We do have the methodology to (rather than destroy) make viruses, but we dont have the intellectual capacity , responds the head of the virology laboratory at Cambridge University Nerea Irigoyen.

There is methodology, not capacity, to create a laboratory virus, but SARS-CoV-2 is far from being the perfect pandemic virus.

He remembers comments on social networks in which he was told that viruses mutate in laboratories. Indeed, Ive been doing it for many years. But it is one thing to do it and quite another to make a perfect pandemic virus. This is not it. We could still do much better so that it could infect more cell types.

70% of human infectious diseases come from viruses, bacteria, or animal parasites. It has always happened. Flu, Ebola, SARS-1, MERS Why dont we accept the normal?, Concludes the scientist.

Read the original post:
Cut and paste: the true genetic engineering of the coronavirus - Explica

Read More...

What does science tell us about Adam and Eve? – Washington University in St. Louis Newsroom

Wednesday, June 17th, 2020

This piece is excerpted from a longer article alum T. Wyatt Reynolds, AB 17, wrote for Mere Orthodoxy.

An atheist, a Christian, and a Jew start talking about science and faith. This might seem like it is either the lead up to a joke or the beginning of a fight. Instead, it was the setting of a meeting convened by S. Joshua Swamidass, MD, associate professor of Pathology & Immunology in the School of Medicine and of Biomedical Engineering in the McKelvey School of Engineering. This meeting gathered scientists and theologians of nearly every stripe to discuss his new book, The Genealogical Adam and Eve (Intervarsity Press). Its argument: that there is no intrinsic contradiction between conventional evolutionary theory and belief in Adam and Eve as a couple specially created six thousand years ago.

The book offers an invitation to skeptics on all sides of the issue to consider either a world where evolution could be true, or a world where Adam and Eve could be real.

Most scientific research to date has focused on whether Adam and Eve could have passed on genetic material to everyone living; however, this doesnt seem to be the type of ancestry the Bible is concerned with. Instead, the Bible is quite concerned with genealogy; extended genealogies fill eleven chapters of Genesis. Who begat whom, and what is the history of their line? This is an entirely different question, and as it turns out, one that can be explored with population genetics. While all genetic ancestors are genealogical ancestors, the inverse is not necessarily true.

So, what does this mean for Adam and Eve? Well, in 2004, a computer simulation of life on Earth was created to test and see when the most recent common ancestor for all humans was. The researchers put higher barriers than historically existed to stack the odds against there being a common ancestor in the recent past. Despite this, the results, published in Nature, found common ancestors only two or three thousand years ago.

Most of these common ancestors are genetic ghosts, meaning that though they are your ancestor, you have inherited no DNA from them. This means that universal ancestors are both surprisingly recent and surprisingly hidden. Swamidass also includes engrossing theological, historical, and philosophical tidbits sprinkled in amidst the science. The book and author are truly making room for many voices at the table of discussion.

The cover art plays a critical role here as it marries DNA strands with a reflective gold foil reminiscent of Makoto Fujimuras paintings. The cover brings together art, theology, and science much as the book itself attempts to create a common ground between these diverse modes of seeing and making sense of the world.

Find more faculty and alumni books on Washington Universitys bookshelf.

Read the rest here:
What does science tell us about Adam and Eve? - Washington University in St. Louis Newsroom

Read More...

Coronavirus threat to global Balanced Salt Solutions Market boosting the growth Worldwide: Market dynamics and trends, efficiencies Forecast 2024 -…

Wednesday, June 17th, 2020

Analysis of the Global Balanced Salt Solutions Market

A recently published market report on the Balanced Salt Solutions market highlights the pitfalls that companies might come across due to the unprecedented outbreak of COVID-19 (Coronavirus). Buyers can request comprehensive market analysis of Coronavirus and its impact on the Balanced Salt Solutions market to mitigate revenue losses.

This market research report on the Balanced Salt Solutions market published by Balanced Salt Solutions derives current insights about the competitive landscape of the Balanced Salt Solutions market. Further, the report unfolds detailed analysis of different segments of the Balanced Salt Solutions market and offers a thorough understanding of the growth potential of each market segment over the assessment period (20XX-20XX).

According to the analysts at Balanced Salt Solutions , the Balanced Salt Solutions market is predicted to register a CAGR growth of ~XX% during the assessment and reach a value of ~US$ XX by the end of 20XX. The report analyzes the micro and macro-economic factors that are projected to influence the growth of the Balanced Salt Solutions market in the coming decade.

Get Free Sample PDF (including COVID19 Impact Analysis, full TOC, Tables and Figures) of Market Report @ https://www.researchmoz.com/enquiry.php?type=S&repid=2530274&source=atm

Key Insights Highlighted in the Report

Segmentation of the Balanced Salt Solutions Market

The presented report elaborate on the Balanced Salt Solutions market into different segments and ponders over the current and future business potentials of each segment. The report showcases the year-on-year growth of each segment and ponders upon the different factors that are likely to influence the growth of each market segment.

The various segments of the Balanced Salt Solutions market explained in the report include:

The following manufacturers are covered:Thermo Fisher ScientificLonza GroupDickinsonEMD MilliporeBectonCorning Life SciencesWheatonPromoCellSigma-AldrichBiological

Segment by RegionsNorth AmericaEuropeChinaJapanSoutheast AsiaIndia

Segment by TypeBy product typeHanks Balanced Salt SolutionGeys Balanced Salt SolutionEarles Balanced Salt SolutionDulbeccos Phosphate Buffered SalineOtherBy end userResearch InstitutesPharmaceutical & Biotechnology Companies

Segment by ApplicationBiopharmaceuticalstherapeuticsStem Cell TechnologyDrug Screening & DevelopmentGenetic EngineeringCancer ResearchOthers

Do You Have Any Query Or Specific Requirement? Ask to Our Industry [emailprotected] https://www.researchmoz.com/enquiry.php?type=E&repid=2530274&source=atm

Important doubts related to the Balanced Salt Solutions market clarified in the report:

Why Choose Balanced Salt Solutions

You can Buy This Report from Here @ https://www.researchmoz.com/checkout?rep_id=2530274&licType=S&source=atm

Read more here:
Coronavirus threat to global Balanced Salt Solutions Market boosting the growth Worldwide: Market dynamics and trends, efficiencies Forecast 2024 -...

Read More...

GM seeds: the debate, and a sowing agitation – The Indian Express

Monday, June 15th, 2020

Written by Parthasarathi Biswas | Pune | Updated: June 12, 2020 12:56:06 pm Genetic engineering aims to transcend the genus barrier by introducing an alien gene in the seeds to get the desired effects. (File Photo)

Last week, Shetkari Sanghatana the farmers union founded by the late leader Sharad Joshi announced fresh plans in its agitation for use of genetically modified seeds. In the current kharif season, farmers would undertake mass sowing of GM seeds for maize, soyabean, mustard brinjal and herbicide tolerant (Ht) cotton, although these are not approved. Farmers had carried out a similar movement last year, too.

What are genetically modified seeds?

Conventional plant breeding involves crossing species of the same genus to provide the offspring with the desired traits of both parents. Genetic engineering aims to transcend the genus barrier by introducing an alien gene in the seeds to get the desired effects. The alien gene could be from a plant, an animal or even a soil bacterium.

Bt cotton, the only GM crop that is allowed in India, has two alien genes from the soil bacterium Bacillus thuringiensis (Bt) that allows the crop to develop a protein toxic to the common pest pink bollworm. Ht Bt, on the other, cotton is derived with the insertion of an additional gene, from another soil bacterium, which allows the plant to resist the common herbicide glyphosate.

In Bt brinjal, a gene allows the plant to resist attacks of fruit and shoot borer.

In DMH-11 mustard, developed by Deepak Pental and colleague in the South Campus of University of Delhi, genetic modification allows cross-pollination in a crop that self-pollinates in nature.

Across the world, GM variants of maize, canola and soyabean, too, are available.

What is the legal position of genetically modified crops in India?

In India, the Genetic Engineering Appraisal Committee (GEAC) is the apex body that allows for commercial release of GM crops. In 2002, the GEAC had allowed the commercial release of Bt cotton. More than 95 per cent of the countrys cotton area has since then come under Bt cotton. Use of the unapproved GM variant can attract a jail term of 5 years and fine of Rs 1 lakh under the Environmental Protection Act ,1989.

Why are farmers rooting for GM crops?

In the case of cotton, farmers cite the high cost of weeding, which goes down considerably if they grow Ht Bt cotton and use glyphosate against weeds. Brinjal growers in Haryana have rooted for Bt brinjal as it reduces the cost of production by cutting down on the use of pesticides.

Unauthorised crops are widely used. Industry estimates say that of the 4-4.5 crore packets (each weighing 400 gm) of cotton sold in the country, 50 lakh are of the unapproved Ht Bt cotton. Haryana has reported farmers growing Bt brinjal in pockets which had caused a major agitation there. In June last year, in a movement led by Shetkari Sanghatana in Akola district of Maharashtra, more than 1,000 farmers defied the government and sowed Ht Bt cotton. The Akola district authorities subsequently booked the organisers.

Express Explainedis now onTelegram. Clickhere to join our channel (@ieexplained)and stay updated with the latest

Environmentalists argue that the long-lasting effect of GM crops is yet to be studied and thus they should not be released commercially. Genetic modification, they say, brings about changes that can be harmful to humans in the long run.

What is the movement about?

The Sanghatana has announced that this year they are going to undertake large-scale sowing of unapproved GM crops like maize, Ht Bt cotton, soyabean and brinjal across Maharashtra. Farmers who plant such variants will put up boards on their fields proclaiming the GM nature of their crop. Anil Ghanwat, president of the union, has said this action will draw attention to the need for introduction of the latest technology in the fields. He said farmers will not be deterred by any action taken against them by the authorities.

The Indian Express is now on Telegram. Click here to join our channel (@indianexpress) and stay updated with the latest headlines

For all the latest Explained News, download Indian Express App.

The Indian Express (P) Ltd

Read the original post:
GM seeds: the debate, and a sowing agitation - The Indian Express

Read More...

Gene-editing company raises 56M in Series A2 to advance gene-editing therapies for curing heart disease – Silicon Canals

Monday, June 15th, 2020

Gene editing is a type of genetic engineering and it is a relatively newer concept. It involves insertion, deletion, modification or replacement of DNA in a living organisms genome. Gene editing could be a powerful tool for helping people suffering from chronic ailments. Some companies are working tirelessly to employ gene editing for solving health problems and Cambridge, Massachusetts based Verve Therapeutics is one of them. The company has now secured 56M in Series A2 to advance gene-editing therapies for reducing the risk of coronary heart disease.

The latest series A2 round for Verve Therapeutics was led by companys existing investor GV, which was formerly known as Google Ventures. Furthermore, current investors ARCH Venture Partners, F-Prime Capital, and Biomatics Capital also joined the investment round. New investors Wellington Management and Casdin Capital also joined in. With the latest funding, the overall funds raised by the company touch a total of 109.5 million.

Coronary heart disease is said to be one of the leading causes of death in the U.S. and worldwide. Verve capital is developing a solution to tackle the issue and lower its risks in adults. It is doing so by developing one-time, gene-editing therapies that can safely edit targeted genes in the liver, which will result in permanent lowering of LDL cholesterol and triglycerides, which are key risk factors causing coronary heart disease. With the freshly acquired funds, the company will focus on advancing its lead program through IND-enabling studies and progress follow-on pipeline programs.

We are immensely grateful to our existing investors for their continued support and commitment to our bold vision to eradicate coronary heart disease, and are very pleased to welcome Wellington Management and Casdin Capital to our investor syndicate, says Sekar Kathiresan, M.D, co-founder and CEO of Verve. This financing is a testament to the tremendous work by the Verve team and will position us to rapidly advance our lead therapeutic candidate through IND-enabling studies and expand our pipeline of development programs. People with heart disease are in urgent need of new therapeutic options, and Verves research to date further underscores the transformative potential of gene editing as a therapeutic approach for these patients.

Image credits: Verve Therapeutics

Stay tuned toSilicon Canalsfor more European technology news

The rest is here:
Gene-editing company raises 56M in Series A2 to advance gene-editing therapies for curing heart disease - Silicon Canals

Read More...

What scientists are learning about COVID-19 from animals – WISHTV.com

Monday, June 15th, 2020

INDIANAPOLIS (WISH) Health experts say a vaccine is the worlds best hope to ending the coronavirus pandemic.

And while there are currently dozens of human clinical trials underway, other trials are enlisting animals. Some are house pets, some live in pastures, and others in tropical rain forests.

Ferrets

Ferrets are vulnerable to many respiratory illnesses found in humans, including lung cancer, cystic fibrosis and the novel coronavirus,thus making them great candidates for experimentation, scientists say.

Researchers now know ferrets can contract and transmit COVID-19. This has a lot to do with how the virus enters the body and attacks the lungs. The mechanism mirrors how COVID-19 attaches to human lungs, scientists say.

Scientists from the Commonwealth Scientific and Industrial Research Organization in Australia have started two pre-clinical trials to test a potential COVID-19 vaccine using the animal.

Monkeys

Scientists from The Jenner Institute at Oxford University began working on a coronavirus vaccine back in 2019. While its not for COVID-19, the virus responsible for this pandemic, its very similar.

The vaccine was tested at the National Institutes of Healths Rocky Mountain Laboratory in Montana. Scientists injected six rhesus monkeys with the 2019 vaccine and then exposed them to the novel coronavirus. Less than a month later, all six monkeys showed no signs of COVID-19.

Cows

Researchers are also looking to cows in an effort to develop a treatment. Scientists at SAB Biotherapeutics in South Dakota, through genetic engineering, created an embryo that contains parts of human chromosomes. The embryo is then implanted into the cow.

The resulting calf then grows into what scientists call a genetically humanized cow. The only overlap between the cow and a person is a portion of their immune system.

The genetically humanized cows are then injected with COVID-19. The cows immune system now similar to a persons would then attack the coronavirus. From there, scientists would look to see if the cows develop antibodies against it. The idea is that these antibodies would then be extracted from the cows blood and used as a drug to combat the coronavirus.

Original post:
What scientists are learning about COVID-19 from animals - WISHTV.com

Read More...

How Receptive are Consumers to Agricultural Biotech? – Food Institute Focus – Food Institute Blog

Monday, June 15th, 2020

After decades of being sidelined by consumers concerned over whether they were safe, foods made with genetically modified organisms, or GMOs, may finally find a place on more meal plates along with other new agricultural biotechnologies aimed at making plants drought- or flood-tolerant and increasing yields.

The changing climate and growing population are pressuring the food system, experts said. At the same time younger generations like Gen Z are interested in the environment and sustainability and are more likely to be open to eating food created with new technologies that could boost yields.

Consumers should think less about the technology and more about what we can do to enhance the sustainability of agriculture, said Pamela Ronald, PhD, professor in the department of plant pathology at the University of California at Davis. There will be different technologies, now and into the future. There is a critical challenge to feed the growing population without destroying the environment.

Dr. Roland and her colleagues developed a rice that can withstand the heavy flooding in Africa and Asia and increase yields. She coauthored a paper entitled Crop Biotechnology and the Future of Food that appeared in the May 19 issue of Nature Food on genetic tools to help increase food production.

By 2050 the global population is predicted to reach 9.7 billion. Meeting this higher food demand, if consumption practices and food waste do not change, requires estimated food production increases of 25% to 200%, she wrote. Cultivated crops using food technologies are part of the solution, she said.

Meanwhile, anti-GMO groups including the Organic Consumers Association in Finland, MN, and the Institute for Agriculture and Trade Policy in Minneapolis, MN, argue there isnt enough research yet on GMOs to assure they are safe to eat.

Some companies even use a non-GMO label as an advantage when marketing to consumers. Meat alternative company Beyond Meat utilized that label to distinguish itself from competitor Impossible Burger, which uses two genetically engineered ingredients: soy leghemoglobin and soy protein.

However, debates over GMO or non-GMO labeling are unlikely to fundamentally change consumers views of GMOs, said William Hallman, PhD, professor and chair of the Department of Human Ecology at Rutgers University, New Brunswick, NJ.

Sales of the Impossible Burger dont appear to be flagging because people are concerned about the fact that it has GMO-based ingredients, he said. In fact, it is more likely that people are attracted to the idea that both the Beyond and Impossible burgers are plant-based, which creates a health halo around the products.

He mentioned most consumers will freely admit they know little about GMOs or gene-editing technologies, so they are not changing their habits about eating GMO foods.

One of the pioneers of GMOs was Norman Borlaug, PhD, who in the 1950s created a disease-resistant, high-yield, semi-dwarf wheat that fed millions of people in Mexico and South Asia.

GMOs continue to be used to relieve famines and get more crop yield out of available land. In January, Zimbabwe quietly lifted its 12-year-old ban on GMO corn in an effort to avert a severe famine, according to Bloomberg News.

The current and anticipated challenges to the food system arent lost in the U.S. Three federal agencies in March got behind an effort to educate consumers about GMOs. The U.S. FDA, USDA, and EPA launched the Feed Your Mind program, which aims to answer questions about what GMOs are, how and why they are made, how they are regulated, and whether they are healthy and safe.

A GMO is a plant, animal, or microorganism that has had its genetic material modified, including transferring DNA from one organism to another. Apples, potatoes, and soybeans are among the many genetically modified foods that are available in supermarkets.

While foods from genetically engineered plants have been available to consumers since the early 1990s and are a common part of todays food supply, there are a lot of misconceptions about them, FDA Commissioner Stephen Hahn, MD, said when the initiative was launched. This initiative is intended to help people better understand what these products are and how they are made. Genetic engineering has created new plants that are resistant to insects and diseases, led to products with improved nutritional profiles, as well as certain produce that dont brown or bruise as easily.

The COVID-19 pandemic could have a role in consumer awareness of potential food shortages, even though distribution issues may be at the root of the problem now, said Oliver Peoples, PhD, president and CEO of Yield10 Bioscience of Woburn, MA, a company that uses the gene-editing technology CRISPR and other technologies to improve crop yields.

The public has gone to the grocery store and seen empty shelves, including basic staples like meats, chicken, and eggs, he said. This has forced many consumers to try genetically modified products that they might have not typically opted to buy before.

Furthermore, the Millennial and Gen Z generations are making a big difference in the acceptability of food made with technology because they are very focused on climate change and sustainability, said Dr. Peoples.

Marketing company Ketchum found that 77% of Gen Z consumers it polled are likely to try food made with technology and 71% are comfortable with its use to grow food (see Food Tech Consumer Perception table below).

This bodes well for food companies, as Gen Z is the newest generation of food consumers with purchasing power, said Bill Zucker, managing director of food at Ketchum.

By Lori Valigra, journalist based in Harrison, ME. Reach her at valigra@gmail.com.

Read more:
How Receptive are Consumers to Agricultural Biotech? - Food Institute Focus - Food Institute Blog

Read More...

Bit Bios enter button for the keyboard to the software of life nabs the company $41.5 million – TechCrunch

Monday, June 15th, 2020

Bit Bio, the new startup which pitches itself as the enter button for the keyboard to the software of life only needed three weeks to raise its latest $41.5 million round of funding.

Originally known as Elpis Biotechnology and named for the Greek goddess of hope, the Cambridge, England-based company was founded by Mark Kotter in 2016 to commercialize technology that can reduce the cost and increase the production capacity for human cell lines. These cells can be used in targeted gene therapies and as a method to accelerate drug discovery at pharmaceutical companies.

The companys goal is to be able to reproduce every human cell type.

Were just at a very crucial time in biology and medicine and the bottleneck that has become really clear is a scalable source of robust human cells, said Kotter. For drug discovery this is important. When you look at failure rates in clinical trials theyre at an all time high thats in direct contradiction to the massive advancements in biotechnology in research and the field.

In the seventeen years since scientists completely mapped the human genome, and eight years since scientists began using the gene editing technology known as CRISPR to edit genetic material, theres been an explosion of treatments based on individual patients genetic material and new drugs developed to more precisely target the mechanisms that pathogens use to spread through organisms.

These treatments and the small molecule drugs being created to stop the spread of pathogens or reduce the effects of disease require significant testing before coming to market and Bit Bios founder thinks his company can both reduce the time to market and offer new treatments for patients.

Its a thesis that had investors like the famous serial biotech entrepreneur, Richard Klausner, who served as the former director of the National Cancer Institute and founder of revolutionary biotech companies like Lyell Immunopharma, Juno, and Grail, leaping at the chance to invest in Bit Bios business, according to Kotter.

Joining Klausner are the famous biotech investment firms Foresite Capital, Blueyard Capital and Arch Venture Partners.

Bit Bio is based on beautiful science. The companys technology has the potential to bring the long-awaited precision and reliability of engineering to the application of stem cells, said Klausner in a statement. Bit Bios approach represents a paradigm shift in biology that will enable a new generation of cell therapies, improving the lives of millions.

Photo: Andrew Brookes/Getty Images

Kotters own path to develop the technology which lies at the heart of Bit Bios business began a decade ago in a laboratory in Cambridge University. It was there that he began research building on the revolutionary discoveries of Shinya Yamanaka, which enabled scientists to transform human adult cells into embryonic stem cells.

What we did is what Yamanaka did. We turned everything upside down. We want to know how each cell is defined and once we know that we can flip the switch, said Kotter. We find out which transcription factors code for a single cell and we turn it on.

Kotter said the technology is like uploading a new program into the embryonic stem cell.

Although the company is still in its early days, it has managed to attract a few key customers and launch a sister company based on the technology. That company, Meatable, is using the same process to make lab-grown pork.

Meatable is the earliest claimant to a commercially viable, patented process for manufacturing meat cells without the need to kill an animal as a prerequisite for cell differentiation and growth.

Other companies have relied on fetal bovine serum or Chinese hamster ovaries to stimulate cell division and production, but Meatablesays it has developed a processwhere it can sample tissue from an animal, revert that tissue to a pluripotent stem cell, then culture that cell sample into muscle and fat to produce the pork products that palates around the world crave.

We know which DNA sequence is responsible for moving an early-stage cell to a muscle cell, says Meatable chief executive Krijn De Nood.

If that sounds similar to Bit Bio, thats because its the same tech just used to make animal instead of human cells.

Image: PASIEKA/SCIENCE PHOTO LIBRARY/Getty Images

If Meatable is one way to commercialize the cell differentiation technology, Bit Bios partnership with the drug development company Charles River Laboratories is another.

We actually do have a revenue generating business side using human cells for research and drug discovery. We have a partnership with Charles River Laboratories the large preclinical contract research organization, Kotter said. That partnership is where we have given early access to our technology to Charles River They have their own usual business clients who want them to help with their drug discovery. The big bottleneck at the moment is access to human cells.

Drug trials fail because the treatments developed either are toxic or dont work in humans. The difference is that most experiments to prove how effective the treatments are rely on animal testing before making the leap to human trials, Kotter said.

The company is also preparing to develop its own cell therapies, according to Kotter. There, the biggest selling point is the increased precision that Bit Bio can bring to precision medicine, said Kotter. If you look at these cell therapies at the moment you get mixed bags of cells. There are some that work and some that have dangerous side effects. We think we can be precise [and] safety is the biggest thing at this point.

The company claims that it can produce cell lines in less than a week with 100 percent purity, versus the mixed bags from other companies cell cultures.

Our moonshot goal is to develop a platform capable of producing every human cell type. This is possible once we understand the genes governing human cell behaviour, which ultimately form the operating system of life, Kotter said in a statement. This will unlock a new generation of cell and tissue therapies for tackling cancer, neurodegenerative disorders and autoimmune diseases and accelerate the development of effective drugs for a range of conditions. The support of leading deep tech and biotech investors will catalyse this unique convergence of biology and engineering.

See original here:
Bit Bios enter button for the keyboard to the software of life nabs the company $41.5 million - TechCrunch

Read More...

How Coronavirus Pandemic Will Impact Nucleic Acid Isolation and Purification Market 2020: Industry Size, Outlook, Share, Demand, Manufacturers and…

Monday, June 15th, 2020

The Nucleic Acid Isolation and Purification Market research report enhanced worldwide Coronavirus COVID19 impact analysis on the market size (Value, Production and Consumption), splits the breakdown (Data Status 2014-2020 and 6 Year Forecast From 2020 to 2026), by region, manufacturers, type and End User/application. This Nucleic Acid Isolation and Purification market report covers the worldwide top manufacturers like (Agilent Technologies, Bio-Rad Laboratories, F.Hoffmann-La-Roche, GE Healthcare, Thermo Fisher Scientific, Abcam, Bioline, Biotechrabbit, BioWORLD, Danaher, Epicentre, Hamilton, New England Biolabs, Omega Bio-tek, Promega, Qiagen, Sigma-Aldrich, Takara Bio) which including information such as: Capacity, Production, Price, Sales, Revenue, Shipment, Gross, Gross Profit, Import, Export, Interview Record, Business Distribution etc., these data help the consumer know about the Nucleic Acid Isolation and Purification market competitors better. It covers Regional Segment Analysis, Type, Application, Major Manufactures, Nucleic Acid Isolation and Purification Industry Chain Analysis, Competitive Insights and Macroeconomic Analysis.

Get Free Sample PDF (including COVID19 Impact Analysis, full TOC, Tables and Figures)of Nucleic Acid Isolation and Purification[emailprotected]https://www.researchmoz.us/enquiry.php?type=S&repid=2380946

Nucleic Acid Isolation and Purification Market report offers comprehensive assessment of 1) Executive Summary, 2) Market Overview, 3) Key Market Trends, 4) Key Success Factors, 5) Nucleic Acid Isolation and Purification Market Demand/Consumption (Value or Size in US$ Mn) Analysis, 6) Nucleic Acid Isolation and Purification Market Background, 7) Nucleic Acid Isolation and Purification industry Analysis & Forecast 20202026 by Type, Application and Region, 8) Nucleic Acid Isolation and Purification Market Structure Analysis, 9) Competition Landscape, 10) Company Share and Company Profiles, 11) Assumptions and Acronyms and, 12) Research Methodology etc.

Scope of Nucleic Acid Isolation and Purification Market:Nucleic acid isolation and purification is a procedure of molecular biology techniques such as cloning, sequencing, polymerase chain reaction and others. These techniques have various applications in the field of genetic engineering, life science research, forensics and molecular diagnostics.

Nucleic acid isolation and purification has provided information to forensic scientists based on downstream analysis and power to individualize biological evidence to match the criminal. Biological evidence such as blood and hair follicles are collected and stored helping forensic investigators to take out nucleic acid for analysis.

In addition, mRNA isolation and purification, RNA isolation and purification, plasmid DNA isolation and purification, total RNA isolation and purification, and PCR clean up. Nucleic acid isolation helps in processing of more sample in less time, minimizes nucleic acid loss ad degradation and increases laboratory efficiency and effectiveness. It also helps in purification of nucleic acid. Column based, reagent based, magnetic bead based and others are some important technology used in nucleic acid isolation and purification. These are used by hospitals, pharmaceuticals, academic research, diagnostic centers, biotechnology companies and food testing and laboratories.

On the basis on the end users/applications,this report focuses on the status and outlook for major applications/end users, shipments, revenue (Million USD), price, and market share and growth rate foreach application.

Hospital Research Others

On the basis of product type, this report displays the shipments, revenue (Million USD), price, and market share and growth rate of each type.

DNA Isolation and Purification RNA Isolation and Purification

Do You Have Any Query Or Specific Requirement? Ask to Our Industry[emailprotected]https://www.researchmoz.us/enquiry.php?type=E&repid=2380946

Geographically, the report includes the research on production, consumption, revenue, Nucleic Acid Isolation and Purification market share and growth rate, and forecast (2020-2026) of the following regions:

Important Nucleic Acid Isolation and Purification Market Data Available In This Report:

Strategic Recommendations, Forecast Growth Areasof the Nucleic Acid Isolation and Purification Market.

Challengesfor the New Entrants,TrendsMarketDrivers.

Emerging Opportunities,Competitive Landscape,Revenue Shareof Main Manufacturers.

This Report Discusses the Nucleic Acid Isolation and Purification MarketSummary; MarketScopeGives A BriefOutlineof theNucleic Acid Isolation and Purification Market.

Key Performing Regions (APAC, EMEA, Americas) Along With Their Major Countries Are Detailed In This Report.

Company Profiles, Product Analysis,Marketing Strategies, Emerging Market Segments and Comprehensive Analysis of Nucleic Acid Isolation and Purification Market.

Nucleic Acid Isolation and Purification Market ShareYear-Over-Year Growthof Key Players in Promising Regions.

What is the (North America, South America, Europe, Africa, Middle East, Asia, China, Japan)production, production value, consumption, consumption value, import and exportof Nucleic Acid Isolation and Purification market?

To Get Discount of Nucleic Acid Isolation and Purification Market:https://www.researchmoz.us/enquiry.php?type=D&repid=2380946

Contact:

ResearchMozMr. Rohit Bhisey,Tel: +1-518-621-2074USA-Canada Toll Free: 866-997-4948Email:[emailprotected]

Browse More Reports Visit @https://www.mytradeinsight.blogspot.com/

See the original post here:
How Coronavirus Pandemic Will Impact Nucleic Acid Isolation and Purification Market 2020: Industry Size, Outlook, Share, Demand, Manufacturers and...

Read More...

If You Invested $1,000 in Fate Therapeutics’ IPO, This Is How Much Money You’d Have Now – The Motley Fool

Monday, June 15th, 2020

If you had invested $1,000 in shares of mid-cap biotech company Fate Therapeutics(NASDAQ:FATE) when it IPO'd, you would have close to $4,823.33 as of markets' close on June 11. That's an astonishing return on investment of 397.5%. In context, the S&P 500 returned 78.8% over the same period.

What's baffling, however, is that the stock's win streak has been entirely ignored by retail investors. In its most recent filings with the Securities and Exchange Commission, institutional investors accounted for almost 100% of the company's ownership. Even so, the company managed to garner much institutional interest despite only having its experimental therapies reach phase 1 status. Could the stock continue its winning streak and deliver riches to investors? Let's find out below.

Image Source: Getty Images

Fate Therapeutics has big buyers excited because it's at the forefront of developing the third generation of cellular immunotherapies. Immunotherapies are treatments that use the power of the body's own immune system to control and eliminate cancer. Currently, the method being investigated by biotechs and researchers around the world is chimeric antigen receptor T-cells (CAR T-cell) immunotherapy, which can help save lives but has a huge price tag.Indeed, after overhead costs, mark-ups, and a three-week manufacturing process, one course of CAR T-cell treatment can cost up to $1.5 million.

Luckily, this is where Fate Therapeutics comes to the rescue with its proprietary induced pluripotent stem cell (iPSC) technology. Using this method, a single stem cell clone can morph into more than 200 different types of cells via genetic engineering, which can then be mass-produced and stored. When cancer patients need a specific type of antibody in their systems, doctors would be able to request the corresponding iPSC on demand from a cell bank.

In previous articles, I discussed the effectiveness of two such therapies,NK100 and FT500, in phase 1 clinical trials. Let's examine yet another one of Fate Therapeutics' promising candidates, FT516.

FT516 is a natural-killer (NK) cell engineered from Fate Therapeutics' master iPSC line with a modified form of the CD16 receptor. Normally, tumor-killing activity from NK cells can be heavily impaired when these cells detach from their targets. FT516, however, is designed to resist detachment upon activation and have a higher affinity for currently approved antibodies that help target cancer cells.

In its phase 1 interim data release, one patient with acute myeloid leukemia who took FT516 (90 million cells per dose) for three weeks as a monotherapy with IL-2 cytokine (cells that regulate the activity of cancer-fighting T-cells) support showed no external evidence of leukemia after treatment.Furthermore, there was evidence of hematopoietic recovery (improvement in the ability to form blood cells of all types), and no circulating leukemia cells were observed in the peripheral blood. FT516 was also found to be well tolerated in this patient.

While the results are very good, observers may rightly point out that the therapy only worked on one patient and has not been compared to current standards of care. However, the patient who recovered after taking FT516 had previously failed multiple rounds of chemotherapy and treatment with standard of care. Hence, it's more likely than not -- save for a miracle -- that the experimental therapy kept the patient alive.

Overall, all three of Fate's pipeline candidates are set to release their clinical data by the end of 2022. Currently, Fate Therapeutics has more than $1.8 billion in potential payouts if these therapies are successful in the development and regulatory stage, and an additional $1.2 billion for hitting certain commercial milestones. The company also has $319 million in cash and investments, including a $100 million cash infusion from Johnson & Johnson's (NYSE:JNJ) Janssen subsidiary in April. Recently, the company closed another round of equity funding from Johnson and Johnson worth at least $214 million, a move that is highly indicative of the pharma giant's confidence in Fate Therapeutics' future prospects.

Image Source: YCharts

Compared to a quarterly net loss of $33 million, the company's capitalization is superb. I think Fate Therapeutics has some truly amazing candidates in its pipeline and is well positioned to enrich investors with a high risk tolerance.

Continued here:
If You Invested $1,000 in Fate Therapeutics' IPO, This Is How Much Money You'd Have Now - The Motley Fool

Read More...

Egg-based coating preserves fresh produce – Feedstuffs

Monday, June 15th, 2020

Eggs that would otherwise be wasted can be used as the base of an inexpensive coating to protect fruits and vegetables, Rice University researchers have discovered.

Brown School of Engineering lab of materials scientist Pulickel Ajayan and colleagues have developed a micron-thick coating that solves problems both for produce and its consumers.

When the coating was applied to produce by spraying or dipping, it showed a remarkable ability to resist rotting for an extended period comparable to standard coatings like wax, but without some of the inherent problems.

The coating provides an outlet for eggs that never reach the market, the researchers suggested, as manufacturers reject 3% of the more than 7 billion eggs produced each year in the U.S. In fact, they estimated that more than 200 million eggs end up in landfills each year.

Reducing food shortages in ways that dont involve genetic modification, inedible coatings or chemical additives is important for sustainable living, Ajayan said. The work is a remarkable combination of interdisciplinary efforts involving materials engineers, chemists and biotechnologists from multiple universities across the U.S.

Along with being edible, the multifunctional coating retards dehydration, provides antimicrobial protection and is largely impermeable both to water vapor to retard dehydration and to gas to prevent premature ripening. The coating is all-natural and washes off with water.

If anyone is sensitive to the coating or has an egg allergy, they can easily eliminate it, Jung said.

Egg whites (albumen) and yolks account for nearly 70% of the coating, the researchers explained. The majority of the rest of the coating consists of nanoscale cellulose extracted from wood -- which serves as a barrier to water and keeps produce from shriveling -- a small amount of curcumin for antimicrobial powers and a splash of glycerol to add elasticity.

Lab tests on dip-coated strawberries, avocadoes, bananas and other fruit showed that they maintained their freshness far longer than uncoated produce. Compression tests showed that coated fruits were significantly stiffer and firmer than uncoated fruits and demonstrated the coatings ability to keep water in the produce, thus slowing the ripening process.

An analysis of freestanding films of the coating showed it to be extremely flexible and able to resist cracking, allowing better protection of the produce. Tests of the films tensile properties showed it to be just as tough as other products, including synthetic films used in produce packaging. Further tests proved the coating to be nontoxic, and solubility tests showed that a thicker-than-usual film is washable. Rinsing in water for a couple of minutes can completely disintegrate it, Ajayan said.

The researchers continue to refine the coatings composition and are considering other source materials.

We chose egg proteins because there are lots of eggs wasted, but it doesnt mean we cant use others, said co-corresponding author Muhammad Rahman, a research scientist in Ajayans Rice lab who mentored and led the team.

Jung noted that the team is testing proteins that could be extracted from plants rather than animal production to make coatings.

Continue reading here:
Egg-based coating preserves fresh produce - Feedstuffs

Read More...

People with blood type O more protected against COVID-19 – studies – The Jerusalem Post

Monday, June 15th, 2020

People with blood type O have less of a chance of getting the COVID-19, according to a number of studies published all over the world during the pandemic. Meanwhile, people with type A might be more vulnerable.

After the pandemic broke out, scientists and doctors alike became puzzled by one question, why are some people more susceptible to contracting, and even succumbing to the disease than others?

According to their blog they did a study that contained more than 750,000 participants. Their preliminary data suggests that O blood type appears to be protective against the virus, and people with that type are between 9-18% less likely that other individuals to have tested positive for the COVID-19 virus.

But how does blood type actually play a role in infection?

Their study included extracting DNA samples from 1,980 COVID-19 patients who were hospitalized for respiratory failure. They scanned the samples using a rapid technique called genotyping, and looked at nearly nine million genetic letters. The researchers then carried out the same experiment on 2,205 blood donors with no evidence of COVID-19. They found that the ill patients shared a number of similar genetic variants compared to those who were not ill.

The scientists were looking for spots in the genome called loci, which they ultimately found. In one of those spots is the gene that determines blood type. Their analysis showed higher risk for A-positive individuals and a protective effect for blood group O.

Blood type is determined by specific sugar molecules that are added to proteins or lipids on our blood cells and other cell types, according to Chemical Science and Engineering news. Those that are in the A blood type group carry A sugar antigens, the same goes for people in the blood type B with B-antigens, however O blood type have neither.

This means that the immune systems of people with type A blood develop antibodies for B antigens, people with type B blood have antibodies for A antigens, and people with type O blood have antibodies for both. Blood type influences blood clotting and a growing body of evidence suggests that COVID-19 pathology often involves overactive blood clotting. People with type O blood have lower levels of proteins that promote blood clotting.

Read this article:
People with blood type O more protected against COVID-19 - studies - The Jerusalem Post

Read More...

Page 14«..10..13141516..2030..»


2024 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick